2 Neil Woodford winning growth stocks I’d buy for my ISA

Are these two of Neil Woodford’s best investments?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Fund manager Neil Woodford has been in the news a lot recently, for all the wrong reasons. Before setting out to build his own fund management company in 2014, Woodford had developed a reputation at his previous employer Invesco, for his market-beating investment performance thanks to a preference for defensive income stocks.

Unfortunately, in recent years this approach has not paid off and several high profile failures have dented his reputation.

However, while the press has focused on the failures, he’s had some tremendous successes as well, which analysts seem to be overlooking.

Record performance 

Burford Capital (LSE: BUR) for example is one of the top five holdings in the LF Woodford Equity Income fund. Over the past five years, this provider of litigation finance has produced a return for investors of 1,332% excluding dividends. Over the past 12 months, including dividends, the stock has returned 80%.

And it looks as if Burford’s growth is only just getting started. Last week the company reported it had managed to more than double income and profit in 2017 and “persistent demand” for its services led to “record new investment commitments” of $1.3bn, “sowing seeds for future profits.” What’s more, even though it’s only a few months old, 2018 is shaping up to be another exciting period for the group. According to last week’s market update, $129m of capital has already been committed to 12 new investments during the first two months of 2018, compared to one single $1m investment in the same period last year.

In my opinion, this activity implies that the company is on track to smash City expectations for growth this year. After 2017’s record performance, analysts are expecting earnings per share to slide by 30% to $0.84 (60p) for 2018. But with the firm looking as if it can break another income record this year, it seems to me as if these forecasts are a tad conservative. 

Analysts have already hiked their earnings targets by 12% over the past month. With this being the case, Burford’s forward P/E of 22.4 does not seem too demanding.

The market’s best company? 

Another Neil Woodford growth stock I’m considering for my ISA is motor claims accident management service business Redde (LSE: REDD).

Redde is a tremendous growth stock. Over the past five years, shares in the company have produced a total return of 42% per annum, making them one of the best performing investments in the entire London market.

The performance is a result of a combination of both earnings growth and multiple expansion. Over the past five years, revenue has doubled as the company has moved from a lossmaking position to an estimated net profit of £36m as expected by City analysts for fiscal 2018. Off the back of this projection, analysts expect the group to earn 11.9p per share for 2018, giving a forward P/E of 14.2. 

Given the fact that growth is expected to slow during 2019 (net profit growth of 6.4% projected) this valuation is a bit on the expensive side. Nevertheless, the company currently pays out all of its earnings to investors via dividends, which means today the shares are trading at a forward dividend yield of 7%, more than double the broader market average. This yield is the primary reason why Redde looks attractive to me.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves owns no share mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

A pastel colored growing graph with rising rocket.
Investing Articles

How much passive income could I make for every £1,000 invested in Aviva shares?

Even a relatively small investment in Aviva shares could generate much greater passive income, particularly if the dividends are reinvested…

Read more »

Close-up of British bank notes
Investing Articles

I’m considering 100 shares in this FTSE 250 gem to aim for £300 a month in dividends

Mark Hartley outlines why a lesser-known banking stock from the FTSE 250's worth considering for an income portfolio in 2024.

Read more »

Investing Articles

History suggests these UK shares might soar if interest rates are cut in August

Some UK shares could rocket if interest rates fall from its 5.25% high next month. And there's one our writer…

Read more »

Female Doctor In White Coat Having Meeting With Woman Patient In Office
Investing Articles

Here’s why H1 results could boost the AstraZeneca share price

The AstraZeneca share price has been a success story in the past five years. With H1 results due, can it…

Read more »

Investing Articles

£17,365 in savings? Here’s how I’d use it to target a £6,700-a-month passive income

Here's how a lump sum investment could pave the way for me to make a four-figure monthly passive income in…

Read more »

Investing Articles

Down more than 10% in 6 months, Fools are backing these 5 UK stocks to reverse that – and then some! – by 2025

Some of our UK free-site writers have put forward their candidates for turnaround stocks!

Read more »

Investing Articles

Down 23%! Should I buy more CrowdStrike shares for my Stocks and Shares ISA?

Sometimes bad news can be good news for long-term investors. But is that the case for CrowdStrike in relation to…

Read more »

Investing Articles

2 UK shares near 52-week lows I’m considering snapping up

These UK shares are loitering near, or at, 52-week lows. Are these prime opportunities for our writer to boost her…

Read more »